Our findings confirm that longer diabetes duration is associated with a lower glycaemic response to GLP-1 RAs [3, 6, 16], probably due to declining beta cell function, as intact insulin secretion is necessary for a robust glycaemic response to this drug class [1, 3]
The DFT patch the signature product lacks independent peer-reviewed evidence for its specific claims, and reviewers note it is not even established that the transdermal delivery mechanism works as described
In patients with T2DM, the reduction in HbA1c is not overtly different between twice daily or once daily administration of lixisenatide [892]
Most previous experiments were comparisons between exenatide (130) and GLP-1, thus exploring the function of the extra residues (3139) in the exenatide C-terminal
North Carolina Medicaid ended coverage of GLP-1s for obesity last month, citing shortfalls in state funding